US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

By N. Howlader, S. Altekruse, Christopher I. Li, V. Chen, C. Clarke, L. Ries, Kathleen A. Cronin. Journal of the National Cancer Institute, 2014

1,438 citations recorded by the source corpus.

BACKGROUND In 2010, Surveillance, Epidemiology, and End Results (SEER) registries began collecting human epidermal growth factor 2 (HER2) receptor status for breast cancer cases. METHODS Breast cancer subtypes defined by joint hormone receptor (HR; estrogen receptor [ER] and progesterone receptor [PR]) and HER2 status were assessed across the 28% of the US population that is covered by SEER registries. Age-specific incidence rates by subtype were calculated for non-Hispanic (NH) white, NH black, NH Asian Pacific Islander (API), and Hispanic women. Joint HR/HER2 status distributions by age, race/ethnicity, county-level poverty, registry, stage, Bloom-Richardson grade, tumor size, and nodal status were evaluated using multivariable adjusted polytomous logistic regression. All statistical tests were two-sided. RESULTS Among case patients with known HR/HER2 status, 36810 (72.7%) were found to be HR(+)/HER2(-), 6193 (12.2%) were triple-negative (HR(-)/HER2(-)), 5240 (10.3%) were HR(+)/HER2(+), and 2328 (4.6%) were HR(-)/HER2(+); 6912 (12%) had unknown HR/HER2 status. NH white women had the highest incidence rate of the HR(+)/HER2(-) subtype, and NH black women had the highest rate of the triple-negative subtype. Compared with women with the HR(+)/HER2(-) subtype, triple-negative patients were more likely to be NH black and Hispanic; HR(+)/HER2(+) patients were more likely to be NH API; and HR(-)/HER2(+) patients were more likely to be NH black, NH API, and Hispanic. Patients with triple-negative, HR(+)/HER2(+), and HR(-)/HER2(+) breast cancer were 10% to 30% less likely to be diagnosed at older ages compared with HR(+)/HER2(-) patients and 6.4-fold to 20.0-fold more likely to present with high-grade disease. CONCLUSIONS In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion (approximately 28%) of the US population.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cb899faff89c794cb9509309360d7d471ab3fd03

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (2018, neutral): “Negative 28/1583 (2) 267/3339 (8) 251/3240 (8) 405/1353 (30)”
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015, background): “About 95% of women with breast cancer present with early-stage cancer withoutmacroscopic evidence ofmetastases (2).”
Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State (2015, methodology): “A recent, large-scale US analysis of breast cancer subtypes using 2010 HR/HER2 data was conducted using 17 NCI Surveillance, Epidemiology, and End Results (SEER) registries covering 28% of the US population (28).”
Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer (2021, background): “The ER positive/ERBB2 negative patients represent 70% of all cases, the ERBB2 positive cases account for 15–20%, and the basal cases denote 15% of all breast cancer cases [6].”
Breast Cancer Treatment: A Review (2019, background): “Score categoryb Low (≤10) Intermediate (11-25) Intermediate (11-25) High (≥26) Low (≤11) Lowintermediate (≤25) High (≥26) Clinical high risk/ MammaPrint low risk Clinical high risk/ MammaPrint low risk”
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “Luminal breast cancers are ER-positive tumors that comprise almost 70% of all cases of breast cancers in Western populations [146].”
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Any 6 (2) 2 (1) 6 (5) 9 (6) 6 (5) 15 (18)”
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020, background): “INTRODUCTION More than 90% of patients with breast cancer are diagnosed with early-stage disease, of whom approximately 70% have cancers that are hormone receptor positive (HR1) and human epidermal growth factor receptor 2 negative (HER22).(1,2) Standard treatment varies depending on risk of recurre”